首页> Cancers> Adjusted Comparison of Outcomes between Patients from CARTITUDE-1 versus Multiple Myeloma Patients with Prior Exposure to PI, Imid and Anti-CD-38 from a German Registry.

Adjusted Comparison of Outcomes between Patients from CARTITUDE-1 versus Multiple Myeloma Patients with Prior Exposure to PI, Imid and Anti-CD-38 from a German Registry.

导出 OA

翻译打印收藏纠错

第一作者： Maximilian,Merz

第一单位： Cell Therapy and Hemostaseology, Department of Hematology, University Hospital of Leipzig, 04103 Leipzig, Germany.

作者： Maximilian,Merz ^[1] ; Hartmut,Goldschmidt ^[2] ; Parameswaran,Hari ^[3] ; Mounzer,Agha ^[4] ; Joris,Diels ^[5] ; Francesca,Ghilotti ^[6] ; Nolen J,Perualila ^[5] ; Jedelyn,Cabrieto ^[5] ; Benjamin,Haefliger ^[7] ; Henrik,Sliwka ^[8] ; Jordan M,Schecter ^[9] ; Carolyn C,Jackson ^[9] ; Yunsi,Olyslager ^[5] ; Muhammad,Akram ^[10] ; Tonia,Nesheiwat ^[10] ; Lenka,Kellermann ^[11] ; Sundar,Jagannath ^[12]

作者单位： Cell Therapy and Hemostaseology, Department of Hematology, University Hospital of Leipzig, 04103 Leipzig, Germany. ^[1] Internal Medicine V and National Center for Tumor Diseases, University Clinic Heidelberg, 69120 Heidelberg, Germany. ^[2] Medical College of Wisconsin, Milwaukee, WI 53226, USA. ^[3] School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA. ^[4] Janssen Pharmaceutica NV, 2340 Beerse, Belgium. ^[5] Janssen-Cilag SpA, 20093 Cologno Monzese, Italy. ^[6] Cilag GmbH International, 6300 Zug, Switzerland. ^[7] Janssen-Cilag Pharma GmbH, 1020 Vienna, Austria. ^[8] Janssen R&D, Raritan, NJ 08869, USA. ^[9] Legend Biotech USA, Inc., Piscataway, NJ 08854, USA. ^[10] Oncology Information Service (O.I.S), 79098 Freiburg, Germany. ^[11] Mount Sinai Medical Center, New York, NY 10029, USA. ^[12]

关键词 CAR-T CARTITUDE-1 adjusted comparison chimeric antigen receptor T-cell therapy cilta-cel ciltacabtagene autoleucel indirect treatment comparison relapsed or refractory multiple myeloma

DOI 10.3390/cancers13235996

PMID 34885106

发布时间 2024-08-19

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交